ALISO VIEJO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the Canaccord Adams 29th Annual Global Growth Conference at 8:00 am EDT on Wednesday, August 12, 2009. The conference will be held at the InterContinental Boston Hotel, August 11-13, 2009.
A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.
Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com
Investor Contact: Matt Clawson Allen & Caron Inc (949) 474-4300 firstname.lastname@example.org
|SOURCE Clarient, Inc.|
Copyright©2009 PR Newswire.
All rights reserved